ArticleEuropean journal of pharmacology2011
G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: roles of Mas-related genes MrgX1 and MrgX2.
Article in European journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 108 citations in OpenAlex.
- Distinct phosphoinositide signatures orchestrate FcεRI versus MRGPRX2 mast cell secretion.iScience · 2026Article
- Loss of Mast cells and histaminergic signaling link diet to platelet-mediated NETosis and mammary cancer recurrence.bioRxiv : the preprint server for biology · 2026Article
- Adenosine-Specific Transcriptional Programs in Murine Connective Tissue-Type Mast Cells.ACS pharmacology & translational science · 2026Article
- Mast Cells and Mas-related G Protein-coupled Receptor X2: Itching for Novel Pathophysiological Insights to Clinical Relevance.Current allergy and asthma reports · 2024Review
- MRGPRX2-mediated mast cell activation by substance P from overloaded human tenocytes induces inflammatory and degenerative responses in tendons.Scientific reports · 2024Article
- Liquiritin inhibits MRGPRX2-mediated pseudo-allergy through the PI3K/AKT and PLCγ signaling pathways.Heliyon · 2023Article
- Mas-related G protein-coupled receptor MRGPRX2 in human basophils: Expression and functional studies.Frontiers in immunology · 2022Article
- Metabolic Consequences of IgE- and Non-IgE-Mediated Mast Cell Degranulation.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Microinjection of pruritogens in NGF-sensitized human skin.Scientific reports · 2021Article
- Lactic acid suppresses MRGPRX2 mediated mast cell responses.Cellular immunology · 2021Article
- Review
- The Multifaceted Mas-Related G Protein-Coupled Receptor Member X2 in Allergic Diseases and Beyond.International journal of molecular sciences · 2021Review
- Review
- Ligands and Signaling of Mas-Related G Protein-Coupled Receptor-X2 in Mast Cell Activation.Reviews of physiology, biochemistry and pharmacology · 2021Article
- Review
- Interleukin-33 Amplifies Human Mast Cell Activities Induced by Complement Anaphylatoxins.Frontiers in immunology · 2020Article
- Osthole, a Natural Plant Derivative Inhibits MRGPRX2 Induced Mast Cell Responses.Frontiers in immunology · 2020Article
- Identification of Novel Mast Cell Activators Using Cell-Based High-Throughput Screening.SLAS discovery : advancing life sciences R & D · 2019Article
- Mast cell corticotropin-releasing factor subtype 2 suppresses mast cell degranulation and limits the severity of anaphylaxis and stress-induced intestinal permeability.The Journal of allergy and clinical immunology · 2019Article
- Store-Operated Calcium Entry via STIM1 Contributes to MRGPRX2 Induced Mast Cell Functions.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Although human mast cells express G protein coupled receptors for the anaphylatoxin C3a, previous studies indicated that C3a causes mast cell degranulation, at least in part, via a C3a receptor-independent mechanism similar to that proposed for polycationic molecules such as compound 48/80. The purpose of the present study was to delineate the receptor specificity of C3a-induced degranulation in human mast cells. We found that C3a, a C3a receptor "superagonist" (E7) and compound 48/80 induced Ca(2+) mobilization and degranulation in a differentiated human mast cell line, LAD2. However, C3a and E7 caused Ca(2+) mobilization in an immature mast cell line, HMC-1 but compound 48/80 did not. We have previously shown that LAD2 cells express MrgX1 and MrgX2 but HMC-1 cells do not. To delineate the receptor specificity for C3a and compound 48/80 further, we generated stable transfectants expressing MrgX1 and MrgX2 in a rodent mast cell line, RBL-2H3 cells. We found that compound 48/80 caused degranulation in RBL-2H3 cells expressing MrgX1 and MrgX2 but C3a did not. By contrast, E7 activated RBL-2H3 cells expressing MrgX2 but not MrgX1. These findings demonstrate that in contrast to previous reports, C3a and compound 48/80 do not use a shared mechanism for mast cell degranulation. It shows that while compound 48/80 utilizes MrgX1 and MrgX2 for mast cell degranulation C3a does not. It further reveals the novel finding that the previously characterized synthetic peptide, C3a receptor "superagonist" E7 activates human mast cells via two mechanisms; one involving the C3a receptor and the other MrgX2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.